LifeMD, Inc. (NASDAQ:LFMD – Get Free Report) has been given a consensus recommendation of “Buy” by the five analysts that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued a report on the stock in the last year is $12.40.
Several research analysts have recently commented on LFMD shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of LifeMD in a research note on Monday, November 11th. Finally, B. Riley initiated coverage on LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 target price for the company.
Read Our Latest Report on LFMD
LifeMD Price Performance
Institutional Trading of LifeMD
Several large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in LifeMD by 251.0% during the first quarter. Russell Investments Group Ltd. now owns 64,927 shares of the company’s stock valued at $667,000 after purchasing an additional 46,428 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of LifeMD by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after purchasing an additional 128,701 shares in the last quarter. Ancora Advisors LLC increased its stake in shares of LifeMD by 97.8% in the 1st quarter. Ancora Advisors LLC now owns 137,760 shares of the company’s stock valued at $1,416,000 after purchasing an additional 68,110 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of LifeMD during the 1st quarter worth $249,000. Finally, Calamos Advisors LLC bought a new stake in shares of LifeMD during the 2nd quarter worth $394,000. Institutional investors and hedge funds own 35.52% of the company’s stock.
LifeMD Company Profile
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
Read More
- Five stocks we like better than LifeMD
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- Stock Market Sectors: What Are They and How Many Are There?
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- The 3 Best Fintech Stocks to Buy Now
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.